MCID: KDN017
MIFTS: 59

Kidney Cancer

Categories: Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Kidney Cancer

MalaCards integrated aliases for Kidney Cancer:

Name: Kidney Cancer 12 43 15
Renal Cancer 12 76 29 55 15
Malignant Neoplasm of Kidney Except Pelvis 12
Malignant Neoplasm of Kidney 73
Malignant Tumour of Kidney 12
Renal Cell Carcinoma 73
Kidney Carcinoma 6
Kidney Neoplasms 44
Renal Carcinoma 73
Kidney Neoplasm 73
Renal Neoplasm 29
Cancer, Kidney 40

Classifications:



External Ids:

Disease Ontology 12 DOID:263
ICD10 33 C64
ICD9CM 35 189.0
MeSH 44 D007680
SNOMED-CT 68 93849006

Summaries for Kidney Cancer

MedlinePlus : 43 You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. The tubes inside filter and clean your blood, taking out waste products and making urine. Kidney cancer forms in the lining of tiny tubes inside your kidneys. Kidney cancer becomes more likely as you age. Risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time. You may have no symptoms at first. They may appear as the cancer grows. See your health care provider if you notice Blood in your urine A lump in your abdomen Weight loss for no reason Pain in your side that does not go away Loss of appetite Tests to diagnose kidney cancer include blood, urine, and imaging tests. You may also have a biopsy. Treatment depends on your age, your overall health and how advanced the cancer is. It might include surgery, chemotherapy, or radiation, biologic, or targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Kidney Cancer, also known as renal cancer, is related to renal cell carcinoma, nonpapillary and melanoma, and has symptoms including flank pain An important gene associated with Kidney Cancer is MTOR (Mechanistic Target Of Rapamycin Kinase), and among its related pathways/superpathways are MicroRNAs in cancer and LncRNA-mediated mechanisms of therapeutic resistance. The drugs Afinitor and Avastin have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and prostate.

Disease Ontology : 12 A urinary system cancer that is located in the kidney.

Wikipedia : 76 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Kidney Cancer

Diseases in the Kidney Cancer family:

Kidney Benign Neoplasm Kidney Carcinoma in Situ
Renal Carcinoma, Familial

Diseases related to Kidney Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 197)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 32.1 GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MET
2 melanoma 30.2 GAS5 H19 HOTAIR MALAT1 MEG3 MIR122
3 clear cell renal cell carcinoma 30.1 MALAT1 MEG3 MET MIR21 MTOR PVT1
4 gallbladder cancer 29.7 H19 HOTAIR MALAT1 MEG3
5 leukemia, acute myeloid 29.7 HOTAIR MALAT1 MEG3 MIR21 MTOR
6 bladder cancer 29.7 GAS5 H19 HIF1A-AS2 HOTAIR MALAT1 MEG3
7 thyroid cancer 29.6 GAS5 H19 HOTAIR MALAT1 MET PVT1
8 prostate cancer 29.4 GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MEG3
9 hepatocellular carcinoma 29.1 GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MEG3
10 gastric cancer 29.1 GAS5 H19 HIF1A-AS2 HOTAIR KCNQ1OT1 MALAT1
11 breast cancer 29.0 EPB41L4A-DT GAS5 H19 HIF1A-AS2 HOTAIR KCNQ1OT1
12 lung cancer 29.0 EPB41L4A-DT GAS5 H19 HIF1A-AS1 HOTAIR KCNQ1OT1
13 colorectal cancer 29.0 GAS5 H19 HIF1A-AS1 HOTAIR KCNQ1OT1 MALAT1
14 multilocular cystic renal neoplasm of low malignant potential 12.1
15 kidney cancer, childhood 12.0
16 kidney carcinoma in situ 12.0
17 hereditary leiomyomatosis and renal cell cancer 11.4
18 collecting duct carcinoma 11.4
19 kidney rhabdoid cancer 11.2
20 renal cell carcinoma, papillary, 1 11.1
21 chromophobe renal cell carcinoma 11.0
22 familial renal papillary carcinoma 11.0
23 birt-hogg-dube syndrome 11.0
24 wilms tumor 1 11.0
25 childhood multilocular cystic kidney neoplasm 10.9
26 congenital mesoblastic nephroma 10.9
27 hereditary paraganglioma-pheochromocytoma syndromes 10.8
28 beckwith-wiedemann syndrome 10.8
29 von hippel-lindau syndrome 10.8
30 denys-drash syndrome 10.8
31 perlman syndrome 10.8
32 wilms tumor 6 10.8
33 kidney hemangiopericytoma 10.8
34 transitional cell carcinoma 10.8
35 kidney sarcoma 10.8
36 kidney clear cell sarcoma 10.8
37 simpson-golabi-behmel syndrome 10.8
38 functionless pituitary adenoma 10.3 HOTAIR MEG3
39 beckwith-wiedemann syndrome due to imprinting defect of 11p15 10.3 H19 KCNQ1OT1
40 triple-receptor negative breast cancer 10.3 HOTAIR MALAT1
41 esophagus squamous cell carcinoma 10.3 HOTAIR MEG3
42 pancreatic neuroendocrine tumor 10.3 MEG3 MTOR
43 malignant pleural mesothelioma 10.3 GAS5 MET PVT1
44 malignant glioma 10.3 GAS5 HOTAIR PVT1
45 hemihyperplasia, isolated 10.3 H19 KCNQ1OT1
46 gastric cardia adenocarcinoma 10.3 H19 HOTAIR MEG3
47 ovarian serous carcinoma 10.3 MIR141 MIR21
48 tongue squamous cell carcinoma 10.3 MALAT1 MEG3 MIR21
49 laryngeal squamous cell carcinoma 10.3 H19 HOTAIR MALAT1 MIR21
50 ovarian epithelial cancer 10.3 H19 HOTAIR MALAT1 MEG3

Graphical network of the top 20 diseases related to Kidney Cancer:



Diseases related to Kidney Cancer

Symptoms & Phenotypes for Kidney Cancer

UMLS symptoms related to Kidney Cancer:


flank pain

Drugs & Therapeutics for Kidney Cancer

FDA approved drugs:

(show all 8)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009
2
Avastin 18 49 BEVACIZUMAB Genentech July 2009
3
Inlyta 18 49 AXITINIB Pfizer January 2012
4
Nexavar 18 49 SORAFENIB TOSYLATE Bayer/Onyx December 2005
5
Proleukin 18 49 ALDESLEUKIN Chiron January 1998
6
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006
7
Torisel 18 49 TEMSIROLIMUS Wyeth May 2007
8
Votrient 18 49 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009

Drugs for Kidney Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 582)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
3
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177
4
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
5
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
6
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
7
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
8
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 557795-19-4, 341031-54-7 5329102
9
Nivolumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 946414-94-4
10
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 98-92-0 936
11
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 284461-73-0 216239 406563
12
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 437-38-7 3345
14
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 2180-92-9, 38396-39-3 2474
15
Zoledronic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 118072-93-8 68740
16
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
17
Caffeine Approved Phase 4,Phase 1 58-08-2 2519
18
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
19
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
20
Dopamine Approved Phase 4,Phase 2,Not Applicable 51-61-6, 62-31-7 681
21
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
22
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
23
Itraconazole Approved, Investigational Phase 4,Phase 3,Not Applicable 84625-61-6 55283
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 50-02-2 5743
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 1177-87-3
26
Acetaminophen Approved Phase 4,Phase 2,Not Applicable 103-90-2 1983
27
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
28
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
29
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
30
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 59-67-6 938
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
32 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
33 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
34 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
37 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 interferons Phase 4,Phase 3,Phase 2,Phase 1
41 Epinephryl borate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
47 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1873)
# Name Status NCT ID Phase Drugs
1 The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy Unknown status NCT01413607 Phase 4
2 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
3 Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
4 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
5 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
6 Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
7 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
8 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
9 Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
10 Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Completed NCT01266837 Phase 4 Everolimus
11 Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
12 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
13 Doxycycline In Lymphangioleiomyomatosis (LAM) Completed NCT00989742 Phase 4 Doxycycline;Placebo
14 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
15 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
16 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
17 Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma Recruiting NCT02399124 Phase 4
18 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. Recruiting NCT01206764 Phase 4 RAD001
19 Effects of Anesthesia on Immunity in Cancer Recruiting NCT03514550 Phase 4 Propofol;Sevoflurane
20 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Recruiting NCT02555748 Phase 4 Pazopanib;Sunitinib
21 Study of Nivolumab for Advanced Cancers in India Recruiting NCT03444766 Phase 4 Nivolumab
22 Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy Recruiting NCT03323021 Phase 4
23 QLB and Laparoscopic Nephrectomy, Postoperative Pain and Recovery Recruiting NCT03339284 Phase 4 Dexamethasone sodium phosphate;Ropivacaine Hydrocloride;Sodium Chloride 9mg/mL
24 Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Laparoscopic Hand-assisted Nephrectomy Recruiting NCT03571490 Phase 4 Ropivacaine;Saline
25 Efficacy of IV Acetaminophen Versus Oral Acetaminophen Recruiting NCT03365622 Phase 4 acetaminophen;Acetaminophen;Placebos;Placebo Oral Tablet
26 Effects of a Neuroscience-based Technique on Post-traumatic Stress Disorder Symptoms, Inflammation, and Survival in Cancer Patients Announced of a Palliative Disease Progression and Their Partners Recruiting NCT03652298 Phase 4
27 An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02596035 Phase 4 Nivolumab
28 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
29 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
30 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Terminated NCT02338570 Phase 4 Everolimus
31 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
32 Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
33 Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy Terminated NCT01486550 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml
34 Exercise for Patients With Renal Cell Cancer Receiving Sunitinib Unknown status NCT00869011 Phase 3
35 Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
36 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Unknown status NCT00003804 Phase 3 vincristine sulfate
37 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
38 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium Unknown status NCT02928692 Phase 3 Minocycline;Placebo
39 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
40 Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer Completed NCT00416429 Phase 3 medroxyprogesterone
41 Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer Completed NCT00416871 Phase 3
42 AE-941 in Treating Patients With Metastatic Kidney Cancer Completed NCT00005995 Phase 3 shark cartilage extract AE-941
43 Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer Completed NCT00002737 Phase 3 chemotherapy;isotretinoin
44 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00018941 Phase 3
45 Kidney-Sparing Surgery Compared With Kidney Removal in Treating Patients With Kidney Cancer Completed NCT00002473 Phase 3
46 Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer Completed NCT00005966 Phase 3 thalidomide
47 Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer Completed NCT00053807 Phase 3 fluorouracil
48 Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer Completed NCT00053820 Phase 3 fluorouracil
49 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
50 Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer Completed NCT00003126 Phase 3 Interleukin-2

Search NIH Clinical Center for Kidney Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: kidney neoplasms

Genetic Tests for Kidney Cancer

Genetic tests related to Kidney Cancer:

# Genetic test Affiliating Genes
1 Renal Neoplasm 29
2 Renal Cancer 29

Anatomical Context for Kidney Cancer

MalaCards organs/tissues related to Kidney Cancer:

41
Kidney, Endothelial, Prostate, Lung, Brain, Testes, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Cancer:

19
The Kidney

Publications for Kidney Cancer

Articles related to Kidney Cancer:

(show top 50) (show all 2215)
# Title Authors Year
1
Radiomics in Kidney Cancer: MR Imaging. ( 30466904 )
2019
2
Prolonged survival of renal cancer patients is concomitant with a higher regucalcin gene expression in tumor tissues: Overexpression of regucalcin suppresses the growth of human renal cell carcinoma cells in vitro. ( 30387835 )
2019
3
Bimetallic titanocene-gold phosphane complexes inhibit invasion, metastasis, and angiogenesis-associated signaling molecules in renal cancer. ( 30368130 )
2019
4
A Study for the Detection of Kidney Cancer Using Fluorescence Emission Spectra and Synchronous Fluorescence Excitation Spectra of Blood and Urine. ( 29800712 )
2018
5
Updates to the Management of Kidney Cancer. ( 29784745 )
2018
6
Lenvatinib for the treatment of kidney cancer. ( 29737893 )
2018
7
Clinical and Molecular Characteristics and Burden of Kidney Cancer Among Hispanics and Native Americans: Steps Toward Precision Medicine. ( 29449090 )
2018
8
Kidney cancer: PDL1 as a biomarker in high-risk RCC. ( 29434371 )
2018
9
Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium: commentary. ( 29742094 )
2018
10
RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition. ( 29389967 )
2018
11
TGF-I^1 targets a microRNA network that regulates cellular adhesion and migration in renal cancer. ( 29079415 )
2018
12
Twist2 and CD24 expression alters renal microenvironment in obesity associated kidney cancer. ( 29424894 )
2018
13
BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. ( 29767721 )
2018
14
Kidney cancer in Saudi Arabia. A 25-year analysis of epidemiology and risk factors in a tertiary center. ( 29738004 )
2018
15
Is imperative partial nephrectomy feasible for kidney cancer with venous thrombus involvement? Outcomes of 42 cases and matched pair analysis with a large radical nephrectomy cohort. ( 29801993 )
2018
16
Hereditary kidney cancer syndromes: Genetic disorders driven by alterations in metabolism and epigenome regulation. ( 29325224 )
2018
17
Broadening the View of Germline Mutations in Kidney Cancer. ( 29978199 )
2018
18
The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. ( 29381020 )
2018
19
Recurrent renal cancer in Birt-Hogg-DubAc syndrome: A case report. ( 29223882 )
2018
20
The incidence of kidney cancer in Iran: a systematic review and meta-analysis. ( 29806587 )
2018
21
Kidney cancer: First-in-class HIF2I+ antagonist safe and effective. ( 29335652 )
2018
22
NICE recommends kidney cancer drug "likely to be less effective" than current treatments after price deal. ( 29449220 )
2018
23
Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer. ( 29368112 )
2018
24
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. ( 29877179 )
2018
25
Rapid intra-operative diagnosis of kidney cancer by ATR-IR spectroscopy of tissue smears. ( 29316381 )
2018
26
Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy. ( 29355171 )
2018
27
Re: Stereotactic Ablative Body Radiotherapy for Inoperable Primary Kidney Cancer: A Prospective Clinical Trial. ( 29783588 )
2018
28
Corrigendum to "A Gene Module-Based eQTL Analysis Prioritizing Disease Genes and Pathways in Kidney Cancer". ( 29977482 )
2018
29
Contemporary surgical outcomes of venous tumour thrombectomy managed with intraoperative Doppler ultrasound for kidney cancer. ( 29787368 )
2018
30
Survival outcomes for advanced kidney cancer patients in the era of targeted therapies. ( 29911113 )
2018
31
Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis. ( 29891937 )
2018
32
Anastomosing hemangioma of the kidney: radiologic and pathologic distinctions of a kidney cancer mimic. ( 29962849 )
2018
33
A Complex Cardiac Mass Originating from Interatrial Septum in a Patient with History of Kidney Cancer: A Case Report and Literature Review. ( 29955398 )
2018
34
Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium. ( 29742093 )
2018
35
Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR. ( 29331568 )
2018
36
HIF2 Inhibitor Joins the Kidney Cancer Armamentarium. ( 29384723 )
2018
37
Kidney cancer in 2017: Challenging and refining treatment paradigms. ( 29335524 )
2018
38
Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. ( 29977349 )
2018
39
PTEN in kidney cancer: A review and meta-analysis. ( 29408173 )
2018
40
Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy. ( 29358781 )
2018
41
Metabolic Footprinting of a Clear Cell Renal Cell Carcinoma in Vitro Model for Human Kidney Cancer Detection. ( 30260228 )
2018
42
Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer. ( 29938199 )
2018
43
Immunotherapy for kidney cancer: status quo and the future. ( 29120911 )
2018
44
SEOM clinical guideline for treatment of kidney cancer (2017). ( 29134564 )
2018
45
Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort. ( 29174942 )
2018
46
Medication use and kidney cancer survival: A population-based study. ( 29226327 )
2018
47
Real-life use of diagnostic biopsies before treatment of kidney cancer: results from a Norwegian population-based study. ( 29249179 )
2018
48
Anticancer activity of Schiff base-Poloxamer P85 combination against kidney cancer. ( 29288416 )
2018
49
Kidney cancer: ccrcc1-4 classification for prediction of relapse. ( 29508851 )
2018
50
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. ( 29549485 )
2018

Variations for Kidney Cancer

ClinVar genetic disease variations for Kidney Cancer:

6 (show all 18)
# Gene Variation Type Significance SNP ID Assembly Location
1 MET NM_001127500.2(MET): c.3743A> G (p.Tyr1248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913246 GRCh37 Chromosome 7, 116423414: 116423414
2 MET NM_001127500.2(MET): c.3743A> G (p.Tyr1248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913246 GRCh38 Chromosome 7, 116783360: 116783360
3 MET NM_001127500.2(MET): c.3335A> G (p.His1112Arg) single nucleotide variant Pathogenic rs121913243 GRCh37 Chromosome 7, 116417464: 116417464
4 MET NM_001127500.2(MET): c.3335A> G (p.His1112Arg) single nucleotide variant Pathogenic rs121913243 GRCh38 Chromosome 7, 116777410: 116777410
5 MET NM_001127500.2(MET): c.3742T> C (p.Tyr1248His) single nucleotide variant Uncertain significance rs121913247 GRCh37 Chromosome 7, 116423413: 116423413
6 MET NM_001127500.2(MET): c.3742T> C (p.Tyr1248His) single nucleotide variant Uncertain significance rs121913247 GRCh38 Chromosome 7, 116783359: 116783359
7 MET NM_001127500.2(MET): c.3334C> T (p.His1112Tyr) single nucleotide variant Likely pathogenic rs121913244 GRCh37 Chromosome 7, 116417463: 116417463
8 MET NM_001127500.2(MET): c.3334C> T (p.His1112Tyr) single nucleotide variant Likely pathogenic rs121913244 GRCh38 Chromosome 7, 116777409: 116777409
9 MET NM_001127500.2(MET): c.3803T> C (p.Met1268Thr) single nucleotide variant Likely pathogenic rs121913245 GRCh37 Chromosome 7, 116423474: 116423474
10 MET NM_001127500.2(MET): c.3803T> C (p.Met1268Thr) single nucleotide variant Likely pathogenic rs121913245 GRCh38 Chromosome 7, 116783420: 116783420
11 MTOR NM_004958.3(MTOR): c.7514G> C (p.Arg2505Pro) single nucleotide variant Likely pathogenic rs1057519777 GRCh37 Chromosome 1, 11169361: 11169361
12 MTOR NM_004958.3(MTOR): c.7514G> C (p.Arg2505Pro) single nucleotide variant Likely pathogenic rs1057519777 GRCh38 Chromosome 1, 11109304: 11109304
13 MTOR NM_004958.3(MTOR): c.6667C> A (p.Gln2223Lys) single nucleotide variant Likely pathogenic rs1057519778 GRCh37 Chromosome 1, 11182179: 11182179
14 MTOR NM_004958.3(MTOR): c.6667C> A (p.Gln2223Lys) single nucleotide variant Likely pathogenic rs1057519778 GRCh38 Chromosome 1, 11122122: 11122122
15 MTOR NM_004958.3(MTOR): c.6644C> A (p.Ser2215Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh37 Chromosome 1, 11184573: 11184573
16 MTOR NM_004958.3(MTOR): c.6644C> A (p.Ser2215Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh38 Chromosome 1, 11124516: 11124516
17 MTOR NM_004958.3(MTOR): c.4379T> C (p.Leu1460Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519779 GRCh37 Chromosome 1, 11217299: 11217299
18 MTOR NM_004958.3(MTOR): c.4379T> C (p.Leu1460Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519779 GRCh38 Chromosome 1, 11157242: 11157242

Cosmic variations for Kidney Cancer:

9 (show top 50) (show all 242)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6941466 XIAP kidney,NS,carcinoma,renal cell carcinoma c.563G>C p.G188A 23:123886225-123886225 20
2 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma c.353T>C p.L118P 3:10146526-10146526 20
3 COSM14380 VHL kidney,NS,carcinoma,renal cell carcinoma c.548C>A p.S183* 3:10149871-10149871 20
4 COSM18350 VHL kidney,NS,carcinoma,renal cell carcinoma c.256C>T p.P86S 3:10142103-10142103 20
5 COSM17957 VHL kidney,NS,carcinoma,renal cell carcinoma c.292T>G p.Y98D 3:10142139-10142139 20
6 COSM14382 VHL kidney,NS,carcinoma,renal cell carcinoma c.245G>C p.R82P 3:10142092-10142092 20
7 COSM14305 VHL kidney,NS,carcinoma,renal cell carcinoma c.266T>A p.L89H 3:10142113-10142113 20
8 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 20
9 COSM17875 VHL kidney,NS,carcinoma,renal cell carcinoma c.234T>G p.N78K 3:10142081-10142081 20
10 COSM17983 VHL kidney,NS,carcinoma,renal cell carcinoma c.500G>A p.R167Q 3:10149823-10149823 20
11 COSM18097 VHL kidney,NS,carcinoma,renal cell carcinoma c.482G>A p.R161Q 3:10149805-10149805 20
12 COSM14425 VHL kidney,NS,carcinoma,renal cell carcinoma c.341-2A>T p.? 3:10146512-10146512 20
13 COSM17872 VHL kidney,NS,carcinoma,renal cell carcinoma c.217C>T p.Q73* 3:10142064-10142064 20
14 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 3:124737785-124737785 20
15 COSM6957851 TSC2 kidney,NS,carcinoma,renal cell carcinoma c.541G>A p.V181M 16:2055461-2055461 20
16 COSM6942356 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.2287C>T p.Q763* 9:132902709-132902709 20
17 COSM6963117 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.1001C>A p.S334* 9:132911481-132911481 20
18 COSM29770 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.508+1G>T p.? 9:132923347-132923347 20
19 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 20
20 COSM10656 TP53 kidney,NS,carcinoma,renal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 20
21 COSM45243 TP53 kidney,NS,carcinoma,renal cell carcinoma c.374C>G p.T125R 17:7675995-7675995 20
22 COSM10647 TP53 kidney,NS,carcinoma,renal cell carcinoma c.404G>T p.C135F 17:7675208-7675208 20
23 COSM44310 TP53 kidney,NS,carcinoma,renal cell carcinoma c.738G>A p.M246I 17:7674225-7674225 20
24 COSM6922197 TP53 kidney,NS,carcinoma,renal cell carcinoma c.97-2A>C p.? 17:7676274-7676274 20
25 COSM45135 TP53 kidney,NS,carcinoma,renal cell carcinoma c.673-1G>T p.? 17:7674291-7674291 20
26 COSM6929752 TBX3 kidney,NS,carcinoma,renal cell carcinoma c.510G>T p.W170C 12:114681026-114681026 20
27 COSM6979493 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2096+1G>A p.? 23:124065947-124065947 20
28 COSM6975582 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.1348A>T p.R450* 23:124057909-124057909 20
29 COSM6023628 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2860C>T p.R954C 23:124081464-124081464 20
30 COSM6963119 SPOP kidney,NS,carcinoma,renal cell carcinoma c.265T>G p.L89V 17:49619321-49619321 20
31 COSM989 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.1130G>A p.R377H 22:23834152-23834152 20
32 COSM6964939 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.987-2A>T p.? 22:23833570-23833570 20
33 COSM1266238 SMARCA4 kidney,NS,carcinoma,renal cell carcinoma c.3575G>A p.R1192H 19:11033318-11033318 20
34 COSM6947611 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.863C>A p.S288* 3:47122264-47122264 20
35 COSM6975580 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.4736C>G p.S1579* 3:47062211-47062211 20
36 COSM4118007 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.3266G>A p.R1089Q 3:47106061-47106061 20
37 COSM4794860 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.5922+1G>A p.? 3:47019759-47019759 20
38 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 2:7020581-7020581 20
39 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 20
40 COSM6925125 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.179C>A p.S60* 23:47169476-47169476 20
41 COSM6922201 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.299G>C p.G100A 23:47171125-47171125 20
42 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 9:123020414-123020414 20
43 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 20
44 COSM6947629 PTCH1 kidney,NS,carcinoma,renal cell carcinoma c.3616C>T p.R1206C 9:95449257-95449257 20
45 COSM6927541 PRKN kidney,NS,carcinoma,renal cell carcinoma c.629T>G p.F210C 6:161973407-161973407 20
46 COSM6913448 POLE kidney,NS,carcinoma,renal cell carcinoma c.4735C>T p.R1579C 12:132642723-132642723 20
47 COSM6972882 PMS1 kidney,NS,carcinoma,renal cell carcinoma c.572T>A p.V191E 2:189818170-189818170 20
48 COSM6923488 PIM1 kidney,NS,carcinoma,renal cell carcinoma c.101T>A p.L34Q 6:37170791-37170791 20
49 COSM6969911 PIK3CG kidney,NS,carcinoma,renal cell carcinoma c.2039T>A p.F680Y 7:106872580-106872580 20
50 COSM763 PIK3CA kidney,NS,carcinoma,renal cell carcinoma c.1633G>A p.E545K 3:179218303-179218303 20

Copy number variations for Kidney Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 166351 3 10158318 10168746 Mutations VHL Renal cancer

Expression for Kidney Cancer

Search GEO for disease gene expression data for Kidney Cancer.

Pathways for Kidney Cancer

Pathways related to Kidney Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.64 MET MIR106B MIR122 MIR141 MIR17 MIR21
2 10.03 HOTAIR MEG3

GO Terms for Kidney Cancer

Cellular components related to Kidney Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.23 H19 MEG3 MIR106B MIR122 MIR141 MIR17

Biological processes related to Kidney Cancer according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.63 MIR106B MIR185 MIR21
2 miRNA mediated inhibition of translation GO:0035278 9.58 MIR106B MIR17 MIR21
3 chromatin silencing GO:0006342 9.49 HOTAIR KCNQ1OT1
4 negative regulation of stress fiber assembly GO:0051497 9.48 MET MIR21
5 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.43 MIR17 MIR21
6 regulation of protein kinase B signaling GO:0051896 9.37 MIR21 MTOR
7 positive regulation of metalloendopeptidase activity GO:1904685 9.32 MIR17 MIR21
8 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.26 MIR17 MIR21
9 cellular response to hypoxia GO:0071456 9.26 MALAT1 MIR106B MIR17 MTOR
10 gene silencing by miRNA GO:0035195 9.23 H19 MEG3 MIR106B MIR122 MIR141 MIR17
11 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.16 MET MIR21

Molecular functions related to Kidney Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR106B MIR141 MIR17 MIR185 MIR21

Sources for Kidney Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....